Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial

Munier, Charles; Eschwège, É.; Grandmottet, P; Isnard, F; Cohen, Jerome; Jl, Bensoussan; Berche, H; Chapiro, O.; André, Patrice; Vague, P; Juhan‐Vague, I.; Bard, Jean‐Marie; Safar, M

doi:10.1002/(sici)1520-7560(200001/02)16:1<2::aid-dmrr75>3.0.co;2-g

Cited by 54 publications

(25 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, 9 clinical trials, [12][13][14][15][16][17][18][19][20] published between 1970 and 2002, met criteria for validity assessment (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

Metformin as Treatment for Overweight and Obese Adults: A Systematic Review

Levri

Slaymaker²,

Yeh³

et al. 2005

The Annals of Family Medicine

View full text Add to dashboard Cite

PURPOSE We wanted to determine whether metformin is an effective medication for treatment of overweight or obese adults who do not have diabetes mellitus or polycystic ovary syndrome (PCOS). METHODSWe searched MEDLINE (1966MEDLINE ( -2003, EMBASE (1986EMBASE ( -2003, Allied and Complementary Medicine Database (1985-2003), International Pharmaceutical Abstracts (1970Abstracts ( -2003, the Cochrane Library, American College of Physicians Journal Club, Database of Abstracts of Reviews of Effects, Cochrane Controlled Trials Register, MEDLINE In-Process & Other Non-Indexed Citations, reference lists of retrieved articles, and articles by selected authors and pharmaceutical manufacturers. Inclusion criteria were being obese or overweight determined by a BMI of 25 kg/m 2 or greater or waist-to-hip ratio (WHR) of more than 0.8, metformin use, and aged 18 years or older. Exclusion criteria were a diagnosis of diabetes mellitus, polycystic ovarian syndrome or descriptors of polycystic ovarian syndrome, human immunodefi ciency virus infection, and concomitant antipsychotic medications. Trials were graded on an 11-point Jadad scale. Only randomized controlled and blinded trials were accepted. Two reviewers independently extracted data from each trial. Primary outcomes measured were changes in BMI, WHR, and weight.RESULTS Fifty-seven potentially relevant studies were initially identifi ed; 48 were excluded because of lack of randomization, lack of blinding, failure to meet inclusion or exclusion criteria, inaccessible outcomes, or improper study design. Nine clinical trials met criteria for validity assessment. Four studies used the parameter of waist-to-hip ratio, 3 studies included BMI, and 8 used weight. Two of the 9 studies showed a small reduction in WHR. CONCLUSION INTRODUCTIONO besity has become a major public health concern in the United States. More than 60% of adults are overweight or obese, 1 with a body mass index (BMI) greater than 25 kg/m.2 Obesity affects persons regardless of age, race, ethnicity, and sex.2 It is associated annually with 400,000 deaths, and associated health care costs exceed $177 billion. 2A combination of genetic, metabolic, behavioral, environmental, cultural, and socioeconomic factors contribute to a person' s body weight.2 An elevated BMI increases the prevalence, morbidity, and mortality of type 2 diabetes mellitus, hypertension, heart disease, stroke, osteoarthritis, respiratory tract disorders, gallstones, certain types of cancer, and psychological disorders. Metformin, the biguanide most widely used for the treatment of type 2 diabetes mellitus, 8 may be useful in aiding weight loss. In diabetic patients, it suppresses endogenous glucose production and may also act as an insulin sensitizer. It also helps diabetic patients lose weight or at least keep their weight stable. 9 In addition to its use in treatment of diabetes, metformin has also become commonly prescribed for patients with polycystic ovary syndrome (PCOS), and its use has resulted in weight reduction in those pat...

show abstract

“…As a result, 9 clinical trials, [12][13][14][15][16][17][18][19][20] published between 1970 and 2002, met criteria for validity assessment (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

Metformin as Treatment for Overweight and Obese Adults: A Systematic Review

Levri

Slaymaker²,

Yeh³

et al. 2005

The Annals of Family Medicine

View full text Add to dashboard Cite

show abstract

“…This effect might be due to the different weight loss mechanisms of the medications such as control of insulin resistance and lowering of the appetite, [16] reduction of gastrointestinal absorption of carbohydrates, [13,15] and decrease of leptin levels [13,17] by metformin as well as reducing caloric intake by modifying appetite and normalizing unusual eating behavior by fluoxetine. [17][18][19][20] The decrease of waist circumference in the groups receiving metformin not in the group receiving only fl uoxetine suggests the effect of metformin is through controlling insulin resistance.…”

Section: Discussionmentioning

confidence: 99%

“…[8][9][10][11] Moreover, metformin has additional health benefi ts independent of its effects on glucose and insulin levels; these include antioxidant activity, weight reduction, improvement of lipid profile, and high blood pressure. [12,13] The mechanisms of its effects on weight loss are not limited to improving insulin resistance, but also by reduction in gastrointestinal absorption of carbohydrates, [12,14] induction of an anorectic and lipolytic effect, [15] and decreasing leptin levels. [13,16] Furthermore, some neuropharmacologic aspects have been considered for weight control; the integration World Journal of Pediatrics…”

Section: Introductionmentioning

confidence: 99%

“…[12,13] The mechanisms of its effects on weight loss are not limited to improving insulin resistance, but also by reduction in gastrointestinal absorption of carbohydrates, [12,14] induction of an anorectic and lipolytic effect, [15] and decreasing leptin levels. [13,16] Furthermore, some neuropharmacologic aspects have been considered for weight control; the integration World Journal of Pediatrics…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Metformin may also have an effect on several CV risk factors, including lipid profile and blood pressure [14]. This drug has beneficial effect on lipid metabolism causing a decrease in total cholesterol LDL, triglycerides, APO B concentrations and by increasing HDL cholesterol level [15]. Metformin is also associated with weight loss and decrease in blood pressure.…”

Section: Biguanidesmentioning

confidence: 99%

Lower Cardiovascular Risk with Diabetic Drugs: A Paradigm Shift from Glucocentricity to Cardio Protectiveness

Mohanty¹

2017

Diabetes Case Rep

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of mortality and morbidity among diabetic patients. There by reducing cardiovascular risk is a major focus of diabetic management. International Diabetes Federation (IDF) in 2014 has projected that 592 million population will be affected by diabetes by the year 2035 from the present status of 387 million out of which 90% will have type 2 diabetes. The prevalence of diabetes and cardiovascular disease is growing exponentially. This rising tide of diabetes around the globe, the double jeopardy of diabetes and cardiovascular disease is infact a time bomb which may result in an explosion of these cardiovascular complications unless aggressive management of diabetes is done. While tight glycaemic control decrease the onset of microvascular complications evidence that it decreases macrovascular complications is limited. Lowering blood glucose levels in patients with diabetes mellitus is a too simplistic goal. The key component being how to lower blood sugar and how much. Diabetes drugs, even within the same "class" yield dramatically different cardiovascular outcomes. Infact a number of diabetic drugs may actually increase the risk of major cardiovascular events posing a challenge for the clinicians to select drugs for patients with type 2 diabetes mellitus. Thus, the treatment of type 2 diabetes needs to be invidualized and complex in which targeting cardiovascular risk factor is an important component. After the updated publication by Nissen and Wolski about the cardiovascular adverse outcomes of rosiglitazone both FDA (Food and Drug Administration) and European medicine agency (EMA) made it mandatory to have CVOT (Cardiovascular outcome trial) as an integral part of drug approval process. Therefore, the need of the hour is to evaluate anti diabetic drugs in relation to cardiovascular risk.This review discusses the available evidence regarding cardiovascular safety of commonly used oral anti-diabetic medications.

show abstract

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial

Cited by 54 publications

References 36 publications

Metformin as Treatment for Overweight and Obese Adults: A Systematic Review

Metformin as Treatment for Overweight and Obese Adults: A Systematic Review

A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity

Lower Cardiovascular Risk with Diabetic Drugs: A Paradigm Shift from Glucocentricity to Cardio Protectiveness

Contact Info

Product

Resources

About